Halozyme Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Halozyme Therapeutics, Inc. announced robust financial results for the second quarter of 2026, driven by substantial growth in royalty and product sales, alongside strategic advancements in its drug delivery technologies.
NASDAQ
Halozyme Therapeutics reports robust Q3 2025 financial results driven by strong royalty growth and announces the strategic acquisition of Elektrofi, expanding its drug delivery technology portfolio.
NASDAQ
Halozyme Therapeutics reports significant revenue and net income growth in Q2 2025, driven by increased royalties from ENHANZE partner product sales and strategic share repurchases.
NASDAQ
10-Q: Halozyme Therapeutics Reports Strong Q1 2025 Results Driven by Royalty and Product Sales Growth
Halozyme Therapeutics announces a successful first quarter in 2025, marked by significant revenue growth driven by increased royalties and product sales.
NASDAQ
Halozyme Therapeutics' Q3 2024 results show significant revenue growth driven by royalties from its ENHANZE drug delivery technology and increased proprietary product sales.
NASDAQ
10-Q: Halozyme Therapeutics Reports Strong Q2 2024 Results Driven by Royalty and Product Sales Growth
Halozyme Therapeutics' Q2 2024 results show significant growth in royalties and proprietary product sales, contributing to a strong financial performance.
NASDAQ
Halozyme Therapeutics reported a strong first quarter of 2024, driven by increased royalty revenues and advancements in its ENHANZE technology collaborations.